Holen Sie sich die Stockscreener-App
5.52
4.83%
-0.28
Handel nachbörslich:
5.52
Schlusskurs vom Vortag:
$5.80
Offen:
$5.59
24-Stunden-Volumen:
17,150
Relative Volume:
0.59
Marktkapitalisierung:
$43.52M
Einnahmen:
$1.11M
Nettoeinkommen (Verlust:
$-28.25M
KGV:
-0.4491
EPS:
-12.2899
Netto-Cashflow:
$-22.13M
1W Leistung:
-10.97%
1M Leistung:
+0.55%
6M Leistung:
+14.76%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.51
$5.60
1-Wochen-Bereich:
$4.97
$6.90
52-Wochen-Spanne:
$3.4962
$50.82
Radiopharm Theranostics Ltd Adr Stock (RADX) Company Profile
Firmenname
Radiopharm Theranostics Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie RADX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RADX
Radiopharm Theranostics Ltd Adr
|
5.52 | 45.12M | 1.11M | -28.25M | -22.13M | -12.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Radiopharm Theranostics Ltd Adr Stock (RADX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-12 | Eingeleitet | B. Riley Securities | Buy |
Radiopharm Theranostics Ltd Adr Aktie (RADX) Neueste Nachrichten
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Jazz Pharmaceuticals (JAZZ) - The Globe and Mail
Radiopharm Theranostics Hosts Webinar Series on Radiopharmaceutical Therapies - MSN
Radiopharm Theranostics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Radiopharm Theranostics Limited: Promising Clinical Developments and Strategic Growth Potential Drive Buy Rating - TipRanks
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody By Investing.com - Investing.com India
FDA clears Radiopharm’s IND application for Lu177-B7H3 antibody - Investing.com
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) By Investing.com - Investing.com India
Radiopharm Theranostics receives FDA IND approval for Betabart (RV-01) - Investing.com
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board - GlobeNewswire Inc.
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board By Investing.com - Investing.com India
Radiopharm Theranostics adds Dr Oliver Sartor to scientific advisory board - Investing.com
Radiopharm Theranostics (NASDAQ:RADX) Now Covered by Brookline Capital Management - Defense World
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital - Investing.com
Radiopharm Theranostics stock initiated with Buy rating at Brookline Capital By Investing.com - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive - Investing.com India
Radiopharm Theranostics receives $4.5 million R&D tax incentive By Investing.com - Investing.com South Africa
OKYO Pharma (NASDAQ:OKYO) Trading Up 1% – Here’s Why - Defense World
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and COMPASS Pathways (CMPS) - The Globe and Mail
Radiopharm signs supply agreement with Cyclotek for prostate cancer drug - Investing.com
Radiopharm wins FDA fast track for cancer imaging agent By Investing.com - Investing.com South Africa
Radiopharm wins FDA fast track for cancer imaging agent - Investing.com
Analysts Offer Insights on NA Companies: Tempus AI, Inc. Class A (TEM) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
radiopharm theranostics begins patient dosing in new trial - Investing.com
radiopharm theranostics begins patient dosing in new trial By Investing.com - Investing.com India
radiopharm theranostics shares preclinical data on new cancer therapy By Investing.com - Investing.com South Africa
radiopharm theranostics shares preclinical data on new cancer therapy - Investing.com
Radiopharm secures lutetium-177 supply agreement By Investing.com - Investing.com South Africa
Radiopharm Theranostics Secures Lutetium-177 Supply Agreement with ITM - TipRanks
Radiopharm secures lutetium-177 supply agreement - Investing.com
Radiopharm advances RAD204 trial with expedited phase By Investing.com - Investing.com India
Radiopharm advances RAD204 trial with expedited phase - Investing.com
RADX: Initiating Coverage – Adding a Radioisotope to Precision Oncology - Zacks Small Cap Research
ThinkEquity initiates Radiopharm stock with Buy, $15 target By Investing.com - Investing.com India
ThinkEquity initiates Radiopharm stock with Buy, $15 target - Investing.com
Radiopharm advances brain cancer diagnosis with new trial By Investing.com - Investing.com South Africa
Radiopharm advances brain cancer diagnosis with new trial - Investing.com
Radiopharm Theranostics says new data confirms positive tumour uptake - Biotech Dispatch
Radiopharm Theranostics Engages in Key Healthcare Conferences - TipRanks
B.Riley sets $15 target on Radiopharm Theranostics stock - Investing.com
Radiopharm Theranostics Announces Director’s Interest Change and Securities Cessation - TipRanks
Radiopharm joins B Riley Radiopharma Conference - Investing.com
Radiopharm reveals positive brain metastases trial data - Investing.com
Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday - Benzinga
Radiopharm completes preclinical tests for cancer drug RAD 402 - Investing.com
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.54% - Investing.com
Radiopharm Achieves Nasdaq Listing of American Depositary Shares - GlobeNewswire
Radiopharm Theranostics (ASX:RAD) Advances Cancer Trials and Expands US Presence - Kalkine Media
Finanzdaten der Radiopharm Theranostics Ltd Adr-Aktie (RADX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):